Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
In October 1984 I arrived at Oxford University, trailing a large steamer trunk containing a couple of changes of clothing and about five dozen textbooks. I had a freshly minted bachelor’s degree in ...
A reverse mortgage allows seniors to access cash from the equity they've built up in their homes. Unlike home equity loans or HELOCs, there's usually no credit score requirement and you don't have to ...
Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Thomas J. Brock is a CFA and CPA with more than 20 ...
James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback